Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India
Shots:
- DCGI has granted the marketing authorization to Enzene’s Romiplostim biosimilar for the treatment of chronic ITP in adults
- The company provides all the three dosage strengths of the product (125mcg- 250mcg- and 500mcg)
- Romiplostim is an Fc-peptide fusion protein that increases platelet production through activation of the thrombopoietin receptor. The company’s first biosimilar Teriparatide has been launched in early 2021 for the treatment of osteoporosis
Ref: PRnewswire | Image: Stat News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com